Zacks: Analysts Anticipate Health Catalyst (NASDAQ:HCAT) to Post -$0.23 Earnings Per Share

Wall Street analysts forecast that Health Catalyst (NASDAQ:HCAT) will report earnings per share (EPS) of ($0.23) for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Health Catalyst’s earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.21). Health Catalyst reported earnings per share of ($0.21) in the same quarter last year, which suggests a negative year over year growth rate of 9.5%. The business is expected to issue its next earnings results on Thursday, August 27th.

On average, analysts expect that Health Catalyst will report full year earnings of ($0.84) per share for the current fiscal year, with EPS estimates ranging from ($1.03) to ($0.72). For the next financial year, analysts anticipate that the business will post earnings of ($0.62) per share, with EPS estimates ranging from ($0.89) to ($0.36). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Health Catalyst.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. The firm had revenue of $45.12 million during the quarter, compared to analyst estimates of $44.12 million. Health Catalyst had a positive return on equity of 30.42% and a negative net margin of 38.74%. The business’s revenue for the quarter was up 28.1% on a year-over-year basis.

A number of research firms recently commented on HCAT. ValuEngine upgraded Health Catalyst from a “hold” rating to a “buy” rating in a research report on Tuesday, February 18th. Raymond James decreased their target price on Health Catalyst from $46.00 to $40.00 and set a “strong-buy” rating on the stock in a research report on Wednesday, May 13th. Royal Bank of Canada boosted their target price on Health Catalyst from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. SunTrust Banks boosted their target price on Health Catalyst from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Finally, Zacks Investment Research downgraded Health Catalyst from a “buy” rating to a “hold” rating in a research report on Tuesday. One analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $40.33.

In other news, insider Linda Llewelyn sold 1,121 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $26.54, for a total transaction of $29,751.34. Following the transaction, the insider now owns 26,498 shares of the company’s stock, valued at $703,256.92. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Paul Horstmeier sold 10,750 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $25.39, for a total value of $272,942.50. Following the transaction, the chief operating officer now directly owns 85,750 shares in the company, valued at approximately $2,177,192.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 134,957 shares of company stock worth $3,623,758. Company insiders own 22.10% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Clearbridge Investments LLC grew its stake in shares of Health Catalyst by 120.4% during the first quarter. Clearbridge Investments LLC now owns 1,011,568 shares of the company’s stock valued at $26,453,000 after buying an additional 552,536 shares during the last quarter. Perceptive Advisors LLC grew its stake in shares of Health Catalyst by 15.9% during the first quarter. Perceptive Advisors LLC now owns 328,698 shares of the company’s stock valued at $8,375,000 after buying an additional 45,000 shares during the last quarter. Capital International Investors grew its stake in shares of Health Catalyst by 73.2% during the first quarter. Capital International Investors now owns 692,700 shares of the company’s stock valued at $18,114,000 after buying an additional 292,700 shares during the last quarter. Tudor Investment Corp Et Al grew its stake in shares of Health Catalyst by 9.1% during the first quarter. Tudor Investment Corp Et Al now owns 23,463 shares of the company’s stock valued at $614,000 after buying an additional 1,960 shares during the last quarter. Finally, Schroder Investment Management Group grew its stake in Health Catalyst by 51.5% in the first quarter. Schroder Investment Management Group now owns 58,720 shares of the company’s stock worth $1,631,000 after purchasing an additional 19,971 shares in the last quarter. 64.09% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ HCAT remained flat at $$28.36 during mid-day trading on Friday. The stock had a trading volume of 422,389 shares, compared to its average volume of 824,448. The company has a market cap of $1.08 billion and a price-to-earnings ratio of -5.37. The company has a quick ratio of 4.95, a current ratio of 4.95 and a debt-to-equity ratio of 0.24. The firm’s 50 day simple moving average is $26.55 and its two-hundred day simple moving average is $31.16. Health Catalyst has a 1 year low of $17.48 and a 1 year high of $49.85.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations primarily in the United States. The company operates through two segments, Technology and Professional services. Its products include cloud-based data platform, analytics software, and professional services.

Read More: Stocks at 52 Week High

Get a free copy of the Zacks research report on Health Catalyst (HCAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.